PMID- 32395981
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1948-7193 (Electronic)
IS  - 1948-7193 (Linking)
VI  - 11
IP  - 10
DP  - 2020 May 20
TI  - Nothing Ventured, Nothing Gained: Regulations Cripple Potentially Life-Saving 
      Research of Illicit Substances.
PG  - 1382-1384
LID - 10.1021/acschemneuro.0c00241 [doi]
AB  - Modern day research, in an attempt to determine the potential therapeutic and 
      adverse effects of illicit substances, is a growing field, but one that faces 
      many regulatory challenges. Due to the potential abuse of illicit substances such 
      as Cannabis, 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide 
      (LSD) and psilocybin, regulations have been conceived with the intent of 
      preventing harm and addiction. However, these regulations have also become a 
      major barrier for the scientific community as they suffocate attempts of the 
      scientists to acquire illicit substances for research purposes. Therefore, it is 
      imperative to modify the current regulations of drug scheduling, leading to a 
      reclassification of illicit substances that would allow for extensive testing in 
      research settings. This reclassification effort could advance the potentially 
      life-saving research of illicit substances.
FAU - Abbott, Kodye L
AU  - Abbott KL
AD  - Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, 
      Alabama 36849, United States.
AD  - Auburn University Research Initiative in Cancer, Auburn University, Auburn, 
      Alabama 36849, United States.
FAU - Gill, Kristina S
AU  - Gill KS
AD  - University of Massachusetts Memorial Medical Center, Worcester, Massachusetts 
      01655, United States.
FAU - Flannery, Patrick C
AU  - Flannery PC
AD  - Rocky Vista University College of Osteopathic Medicine, Parker, Colorado 80134, 
      United States.
FAU - Boothe, Dawn M
AU  - Boothe DM
AD  - Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, 
      Alabama 36849, United States.
AD  - Auburn University Research Initiative in Cancer, Auburn University, Auburn, 
      Alabama 36849, United States.
FAU - Dhanasekaran, Muralikrishnan
AU  - Dhanasekaran M
AD  - Auburn University Research Initiative in Cancer, Auburn University, Auburn, 
      Alabama 36849, United States.
AD  - Department of Drug Discovery and Development, Auburn University, Auburn Alabama 
      36849, United States.
FAU - Pondugula, Satyanarayana R
AU  - Pondugula SR
AD  - Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, 
      Alabama 36849, United States.
AD  - Auburn University Research Initiative in Cancer, Auburn University, Auburn, 
      Alabama 36849, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - United States
TA  - ACS Chem Neurosci
JT  - ACS chemical neuroscience
JID - 101525337
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - *Hallucinogens/therapeutic use
MH  - Humans
MH  - Lysergic Acid Diethylamide
MH  - *N-Methyl-3,4-methylenedioxyamphetamine
MH  - Psilocybin
MH  - *Substance-Related Disorders/drug therapy
OTO - NOTNLM
OT  - Drug abuse
OT  - LSD
OT  - MDMA
OT  - cannabis
OT  - drug interactions
OT  - drug scheduling
EDAT- 2020/05/13 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1021/acschemneuro.0c00241 [doi]
PST - ppublish
SO  - ACS Chem Neurosci. 2020 May 20;11(10):1382-1384. doi: 
      10.1021/acschemneuro.0c00241. Epub 2020 May 12.